Darwin Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Darwin Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$78.2K	Buy	+103	New	+$77.8K	0.02%	230
2026 Q2	–	Hold	0	–	–	–	596
2021 Q3	–	Sell	-473	Closed	-$264K	–	183
2021 Q2	$264K	Buy	+473	New	+$240K	0.04%	150
2020 Q3	–	Sell	-4,728	Closed	-$2.95M	–	170
2020 Q2	$2.95M	Buy	+4,728	New	+$2.68M	0.75%	47

Other funds holding REGN

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Darwin Wealth Management's REGN Position: Q3 2026 in Review

Darwin Wealth Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 103 shares worth $78.2K. The stake represents 0.02% of the portfolio and ranks #230 among its holdings. This is a return to the name: Darwin Wealth Management previously reported a position in REGN as recently as Q2 2021.

Darwin Wealth Management first reported a position in REGN in Q2 2020 and has held it in 3 quarters since. The position peaked at $2.95M in Q2 2020. 895 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Darwin Wealth Management held 103 shares of Regeneron Pharmaceuticals worth $78.2K as of Q3 2026.
Regeneron Pharmaceuticals was a new Darwin Wealth Management position in Q3 2026.
Regeneron Pharmaceuticals made up 0.02% of Darwin Wealth Management's portfolio in Q3 2026, its #230 holding.
Darwin Wealth Management first reported a position in Regeneron Pharmaceuticals in Q2 2020 and has held it in 3 quarters since.
Darwin Wealth Management's Regeneron Pharmaceuticals position peaked at $2.95M in Q2 2020.
895 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Darwin Wealth Management's 13F filing for Q3 2026, filed 9 Nov 2026.